AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01371487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Oral/once-daily single doses on Day 1 of Periods 1 and 2
Study NCT01554839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family of Heroes
Description: One hour online educational tool
Study NCT01554839 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline and Follow up Surveys
Description: Baseline and follow up questionaires completed online
Study NCT03081104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hystroscopy
Description: The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
Study NCT03081104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
Study NCT01554839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline and Follow up Surveys
Description: Baseline and follow up questionaires completed online
Study NCT01768598 — intervention group
Intervention type: OTHER
Intervention: Fracture - Boys
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
Study NCT01768598 — intervention group
Intervention type: OTHER
Intervention: Fracture - Girls
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
Study NCT01768598 — intervention group
Intervention type: OTHER
Intervention: Non Fracture - Boys
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
Study NCT01768598 — intervention group
Intervention type: OTHER
Intervention: Non Fracture - Girls
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
Study NCT04282226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
Study NCT04282226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
Study NCT03081104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
Study NCT03682965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-lymphatic allergenic extract
Description: Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
Study NCT03682965 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intra-lymphatic placebo
Description: The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
Study NCT00442117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide DPI
Description: Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
Study NCT02140138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9104
Study NCT02357849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: see arm description
Study NCT02357849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: see arm description
Study NCT03214692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Oral intake of GA in powder from30 grams per day
Study NCT01155297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration.
Study NCT01155297 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and metabolic exercises
Description: At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
Study NCT00472472 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel coated balloon catheter (device with drug)
Description: PTA vs Paccocath
Study NCT00472472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel coated balloon catheter (device with drug)
Description: PTA vs Paccocath
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Doses to be determined following the completion of Phase I of the study.
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 250mg
Description: 250mg/d,q.d.,p.o.every 21 days.
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 500mg
Description: 500mg/d,q.d.,p.o.every 21 days.
Study NCT03201146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 750mg
Description: 750mg/d,q.d.,p.o.every 21 days.
Study NCT01368393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
Study NCT01368393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham acupuncture
Description: Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
Study NCT03157973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education intervention
Description: eHealth tool and standardized nurse-led follow-up.
Study NCT00297362 — intervention group
Intervention type: DRUG
Intervention: Galantamine hydrobromide
Description: 247 patients with diagnosed mild to moderate Alzheimer disease.
Study NCT03984331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fish skin
Description: One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Study NCT03984331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cadaver skin
Description: One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Study NCT03378154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation in infants with Macintosh
Description: Orotracheal intubation in infants using Macintosh laryngoscope
Study NCT03378154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation in infants with King vision
Description: Orotracheal intubation in infants with King vision videolaryngoscope
Study NCT03496467 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac PPDS
Description: A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
Study NCT03496467 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PPDS
Description: A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
Study NCT01626352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
Study NCT01626352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
Study NCT04762147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol, the group P
Description: The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Study NCT00369824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: One dose of vaccine administered intramuscularly
Study NCT00768950 — intervention group
Intervention type: PROCEDURE
Intervention: Capsule endoscopy examination
Description: Examination of the small bowel with endoscopic videocapsule
Study NCT00768950 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Endoscopic examination of the large bowel and terminal ileum
Study NCT03827265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
Study NCT04762147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, group-F administered as an active comparator
Description: The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Study NCT01062594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
Study NCT01062594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of exercise
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
Study NCT01062594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program
Description: Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
Study NCT01287533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: monthly dosage of ibandronate 150mg
Study NCT01287533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: monthly dosage of placebo
Study NCT00645567 — intervention group
Intervention type: DEVICE
Intervention: Unassisted Manual Transfer
Description: No device assistance
Study NCT00645567 — intervention group
Intervention type: DEVICE
Intervention: Standard Transfer Board
Description: Flat surface board
Study NCT00645567 — intervention group
Intervention type: DEVICE
Intervention: Glide n' Go
Description: Flip down power lift chair
Study NCT00645567 — intervention group
Intervention type: DEVICE
Intervention: Easy Reach lift
Description: Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
Study NCT00645567 — intervention group
Intervention type: DEVICE
Intervention: Ryno lift
Description: Lift for the wheelchair
Study NCT02583802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ear pills
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
Study NCT02583802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shengmai capsule
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
Study NCT00125190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin) for a period of 86 weeks
Description: Once a day rhIGF-1 injections
Study NCT02140138 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CV9104
Study NCT02140138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle free injection device (Tropis®)
Study NCT01972009 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac catheterisation
Description: Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
Study NCT01344837 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01344837 — intervention group
Intervention type: OTHER
Intervention: Immunohistochemistry Staining Method
Description: Correlative studies
Study NCT01344837 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Correlative studies
Study NCT01344837 — intervention group
Intervention type: GENETIC
Intervention: Microarray Analysis
Description: Correlative studies
Study NCT01344837 — intervention group
Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Correlative studies
Study NCT01344837 — intervention group
Intervention type: GENETIC
Intervention: Western Blotting
Description: Correlative studies
Study NCT02939937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
Study NCT02939937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
Study NCT02953782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT03827265 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
Study NCT02953782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously
Study NCT04272801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen, letrozole, anastrozole, or exemestane
Description: choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
Study NCT04272801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes
Description: Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy
Study NCT02688049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/mesenchymal stem cells transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study NCT02688049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/neural stem cells transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study NCT01889966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral Sildenafil 3 x 20 mg for 90 days
Study NCT03994263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITind device implant
Description: device implanted for 5-7 days
Study NCT03605719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT03605719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT03605719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02140138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: needle free injection device (Tropis®)
Study NCT00539292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary placement of a spring-loaded silo
Study NCT00539292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Closure
Description: primary closure of abdomen
Study NCT02801071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15g L-citrulline daily p.o.
Study NCT02801071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02613806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmeditomidine
Description: Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Study NCT02613806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Study NCT02234739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 2-week long intravenous instillation of voriconazole
Study NCT05503212 — intervention group
Intervention type: OTHER
Intervention: Conservative treatment (CT)
Description: Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
Study NCT05503212 — intervention group
Intervention type: OTHER
Intervention: Intravenous thrombolysis (IVT)
Description: Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
Study NCT05503212 — intervention group
Intervention type: OTHER
Intervention: Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)
Description: Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis